KR101865689B1 - 부프레노르핀을 포함하는 주입가능한 유동성 조성물 - Google Patents

부프레노르핀을 포함하는 주입가능한 유동성 조성물 Download PDF

Info

Publication number
KR101865689B1
KR101865689B1 KR1020127032282A KR20127032282A KR101865689B1 KR 101865689 B1 KR101865689 B1 KR 101865689B1 KR 1020127032282 A KR1020127032282 A KR 1020127032282A KR 20127032282 A KR20127032282 A KR 20127032282A KR 101865689 B1 KR101865689 B1 KR 101865689B1
Authority
KR
South Korea
Prior art keywords
buprenorphine
flowable composition
poly
lactide
glycolide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020127032282A
Other languages
English (en)
Korean (ko)
Other versions
KR20130135026A (ko
Inventor
리차드 엘 노튼
앤드류 왓킨스
밍싱 주오우
Original Assignee
인디비어 유케이 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42471306&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101865689(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 인디비어 유케이 리미티드 filed Critical 인디비어 유케이 리미티드
Publication of KR20130135026A publication Critical patent/KR20130135026A/ko
Application granted granted Critical
Publication of KR101865689B1 publication Critical patent/KR101865689B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020127032282A 2010-06-08 2011-06-06 부프레노르핀을 포함하는 주입가능한 유동성 조성물 Expired - Fee Related KR101865689B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1009549.5 2010-06-08
GB1009549.5A GB2481018B (en) 2010-06-08 2010-06-08 Injectable flowable composition comprising buprenorphine
PCT/GB2011/051057 WO2011154724A2 (en) 2010-06-08 2011-06-06 Compositions

Publications (2)

Publication Number Publication Date
KR20130135026A KR20130135026A (ko) 2013-12-10
KR101865689B1 true KR101865689B1 (ko) 2018-06-08

Family

ID=42471306

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127032282A Expired - Fee Related KR101865689B1 (ko) 2010-06-08 2011-06-06 부프레노르핀을 포함하는 주입가능한 유동성 조성물

Country Status (32)

Country Link
US (1) US8921387B2 (enExample)
EP (3) EP3360538B1 (enExample)
JP (2) JP5986072B2 (enExample)
KR (1) KR101865689B1 (enExample)
CN (1) CN103079544B (enExample)
AU (1) AU2011263478B2 (enExample)
BR (1) BR112012031290A2 (enExample)
CA (1) CA2801676C (enExample)
CL (1) CL2012003462A1 (enExample)
CO (1) CO6670529A2 (enExample)
CY (1) CY1120761T1 (enExample)
DK (2) DK2579874T3 (enExample)
ES (2) ES2656938T3 (enExample)
FI (1) FI3360538T3 (enExample)
GB (2) GB2513267B (enExample)
HR (1) HRP20180118T1 (enExample)
HU (1) HUE038275T2 (enExample)
IL (2) IL223488A (enExample)
LT (1) LT2579874T (enExample)
MX (1) MX339209B (enExample)
MY (1) MY171625A (enExample)
NO (1) NO2579874T3 (enExample)
NZ (1) NZ604026A (enExample)
PL (1) PL2579874T3 (enExample)
PT (1) PT2579874T (enExample)
RS (1) RS56820B1 (enExample)
RU (1) RU2607498C2 (enExample)
SG (1) SG186200A1 (enExample)
SI (1) SI2579874T1 (enExample)
SM (1) SMT201800038T1 (enExample)
WO (1) WO2011154724A2 (enExample)
ZA (1) ZA201209233B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8470359B2 (en) 2000-11-13 2013-06-25 Qlt Usa, Inc. Sustained release polymer
GB2481017B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
GB2513267B (en) 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
WO2013126552A1 (en) * 2012-02-21 2013-08-29 Auburn University Buprenorphine nanoparticle composition and methods thereof
JP6279547B2 (ja) 2012-04-17 2018-02-14 パーデュー、ファーマ、リミテッド、パートナーシップ オピオイド誘発性有害薬力学的応答を治療するためのシステムおよび方法
IL296882A (en) * 2012-07-26 2022-12-01 Camurus Ab Opioid formulations
KR102098980B1 (ko) 2012-07-26 2020-04-08 카무러스 에이비 오피오이드 제형
EP2931253A1 (en) * 2012-12-13 2015-10-21 Heron Therapeutics, Inc. Pharmaceutical composition comprising antiemetic compounds and polyorthoester
US9636308B2 (en) 2013-03-15 2017-05-02 Oakwood Laboratories LLC High drug load buprenorphine microspheres and method of producing same
US9393211B2 (en) * 2013-03-15 2016-07-19 Oakwood Laboratories LLC High drug load buprenorphine microspheres and method of producing same
WO2014143635A1 (en) * 2013-03-15 2014-09-18 Heron Therapeutics, Inc. Compositions of a polyorthoester and an aprotic solvent
GB201404139D0 (en) * 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
EP3509601A1 (en) 2014-04-21 2019-07-17 Heron Therapeutics, Inc. A pharmaceutical composition comprising a delivery system, an amide-type local anesthetic, and meloxicam
HUE052224T2 (hu) * 2014-04-21 2021-04-28 Heron Therapeutics Inc Poliortoészterbõl és szerves sav segédanyagból álló készítmények
US9801945B2 (en) 2014-04-21 2017-10-31 Heron Therapeutics, Inc. Long-acting polymeric delivery systems
CA2946281C (en) 2014-04-21 2022-12-13 Heron Therapeutics, Inc. Long-acting polymeric delivery systems
CN106470999B (zh) 2014-04-28 2018-11-13 奥佛麦德公司 叔丁啡二聚体及其在治疗肠胃失调中的应用
GB201419091D0 (en) * 2014-10-27 2014-12-10 Camurus Ab Formulations
WO2016071767A1 (en) * 2014-11-07 2016-05-12 Indivior Uk Limited Buprenorphine dosing regimens
US10786515B2 (en) 2015-08-03 2020-09-29 Tolmar International Limited Liquid polymer delivery system for extended administration of drugs
FI3377041T3 (fi) 2015-11-16 2023-11-30 Medincell S A Menetelmä farmaseuttisesti aktiivisten pääainesosien morselloimiseksi ja/tai kohdentamiseksi synoviaalikudokseen
CA3033046C (en) * 2016-09-13 2021-09-07 Alar Pharmaceuticals Inc. Sustained-release buprenorphine formulations
EP3638240A2 (en) 2017-06-16 2020-04-22 Indivior UK Limited Methods to treat opioid use disorder
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
AU2019209416A1 (en) 2018-01-22 2020-07-30 Foresee Pharmaceuticals Co., Ltd. Pharmaceutical composition for sustained release delivery of buprenorphine
AR117426A1 (es) * 2018-05-11 2021-08-04 Alar Pharmaceuticals Inc Formulaciones inyectables de acción prolongada y formas cristalinas de derivados de buprenorfina
EP3863712A4 (en) 2018-10-11 2022-07-20 Indivior UK Limited Buprenorphine to treat respiratory depression
US12403291B2 (en) 2019-08-30 2025-09-02 Intersect Ent, Inc. Submucosal bioresorbable drug eluting platform
CN118831057A (zh) * 2023-04-25 2024-10-25 深圳善康医药科技股份有限公司 丁丙诺啡植入剂及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006508127A (ja) * 2002-11-06 2006-03-09 アルザ・コーポレーション 制御された放出性デポー剤配合物
JP2008520547A (ja) * 2004-10-04 2008-06-19 キューエルティー ユーエスエー，インコーポレイテッド． 眼部送達のためのポリマー送達処方
WO2009091737A2 (en) * 2008-01-14 2009-07-23 Dunn Research & Consulting, Llc Low viscosity liquid polymeric delivery system

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
DE69534780T2 (de) 1994-04-08 2006-10-05 Qlt Usa Inc., Fort Collins Flüssige Zusammensetzungen zur Arzneistoffabgabe
US20030211157A1 (en) * 1996-05-06 2003-11-13 Simon David Lew Semi-sol delivery blend for water soluble molecules
US6143314A (en) * 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US6461631B1 (en) 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
SI2561860T1 (en) * 2002-05-31 2018-05-31 Titan Pharmaceuticals, Inc. An implantable polymeric device for prolonged release of buprenorphine
JP2007525429A (ja) * 2003-03-11 2007-09-06 キューエルティー ユーエスエー，インコーポレイテッド． 細胞スケジュール依存性抗癌剤のための処方
AU2005304435B8 (en) * 2004-11-10 2011-06-23 Tolmar Therapeutics, Inc. A stabilized polymeric delivery system
HUE025842T2 (en) 2007-02-15 2016-04-28 Tolmar Therapeutics Inc Poly (lactide / glycolide) with reduced fracture properties and methods for producing polymers
GB2513267B (en) 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006508127A (ja) * 2002-11-06 2006-03-09 アルザ・コーポレーション 制御された放出性デポー剤配合物
JP2008520547A (ja) * 2004-10-04 2008-06-19 キューエルティー ユーエスエー，インコーポレイテッド． 眼部送達のためのポリマー送達処方
WO2009091737A2 (en) * 2008-01-14 2009-07-23 Dunn Research & Consulting, Llc Low viscosity liquid polymeric delivery system

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Richard A. Graves et al, ‘In Vitro Dissolution Method for Evaluation of Buprenorphine In Situ Gel Formulation: A Technical Note’, AAPS PharmSciTech, 2007, Vol.8, No.3, E1-E4 *
Richard A. Graves et al, ‘In Vitro Dissolution Method for Evaluation of Buprenorphine In Situ Gel Formulation: A Technical Note’, AAPS PharmSciTech, 2007, Vol.8, No.3, E1-E4*

Also Published As

Publication number Publication date
WO2011154724A2 (en) 2011-12-15
SG186200A1 (en) 2013-01-30
NO2579874T3 (enExample) 2018-06-09
JP5986072B2 (ja) 2016-09-06
GB201413064D0 (en) 2014-09-03
RS56820B1 (sr) 2018-04-30
MX339209B (es) 2016-04-15
AU2011263478A1 (en) 2013-01-10
WO2011154724A3 (en) 2012-07-12
DK3360538T3 (da) 2023-03-06
MY171625A (en) 2019-10-21
LT2579874T (lt) 2018-02-12
EP3360538B1 (en) 2023-02-15
RU2607498C2 (ru) 2017-01-10
JP6251774B2 (ja) 2017-12-20
FI3360538T3 (fi) 2023-03-22
WO2011154724A9 (en) 2012-08-16
IL254417A0 (en) 2017-11-30
CN103079544B (zh) 2017-06-09
PT2579874T (pt) 2018-01-29
JP2016155865A (ja) 2016-09-01
EP2579874A2 (en) 2013-04-17
GB201009549D0 (en) 2010-07-21
ES2939612T3 (es) 2023-04-25
CA2801676A1 (en) 2011-12-15
GB2481018B (en) 2015-03-18
GB2513267B (en) 2015-03-18
GB2481018A (en) 2011-12-14
ES2656938T3 (es) 2018-03-01
CN103079544A (zh) 2013-05-01
EP3360538A1 (en) 2018-08-15
BR112012031290A2 (pt) 2016-11-01
JP2013533230A (ja) 2013-08-22
DK2579874T3 (da) 2018-01-29
CL2012003462A1 (es) 2013-04-01
ZA201209233B (en) 2014-04-30
EP2579874B1 (en) 2018-01-10
AU2011263478B2 (en) 2015-01-22
HRP20180118T1 (hr) 2018-03-09
HUE038275T2 (hu) 2018-10-29
SMT201800038T1 (it) 2018-03-08
PL2579874T3 (pl) 2018-05-30
EP4218720A1 (en) 2023-08-02
MX2012014335A (es) 2013-03-05
SI2579874T1 (en) 2018-03-30
US8921387B2 (en) 2014-12-30
CO6670529A2 (es) 2013-05-15
NZ604026A (en) 2015-01-30
RU2012157244A (ru) 2014-07-20
US20130210853A1 (en) 2013-08-15
GB2513267A (en) 2014-10-22
KR20130135026A (ko) 2013-12-10
CY1120761T1 (el) 2019-12-11
IL223488A (en) 2017-10-31
CA2801676C (en) 2018-08-07

Similar Documents

Publication Publication Date Title
KR101865689B1 (ko) 부프레노르핀을 포함하는 주입가능한 유동성 조성물
US10592168B1 (en) Injectable flowable composition comprising buprenorphine
CA2687979C (en) Sustained delivery formulations of risperidone compounds
US8975270B2 (en) Injectable flowable composition comprising buprenorphine
HK40097172A (en) Injectable flowable composition comprising buprenorphine
HK1184056B (en) Injectable flowable composition comprising buprenorphine
HK1184056A (en) Injectable flowable composition comprising buprenorphine

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20210602

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20210602

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000